MARIBAVIR FOR CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE INTERNATIONAL REAL-WORLD STUDY OF IDWP OF EBMT (EBMT 2026) - Feb 7, 2026 - Abstract #OS09-08; Pres time: Mar 24, 2026; 10:03 AM - 10:12 AM; Location: N104; "The graft-versus-host disease prophylaxis was post-transplant cyclophosphamide-based in 63 (55%); 60 (52%) had received prophylaxis with letermovir. This large real-world study confirms MBV as an effective and well-tolerated option for CMV infection and disease in allo-HCT recipients"
Real-world • Real-world evidence • Retrospective data • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Ocular Inflammation • Ophthalmology • Pneumonia • Respiratory Diseases • Retinal Disorders • Solid Organ Transplantation • Transplantation
|
|
Annalisa Paviglianiti1; Per Ljungman2; Rafael de la Camara3; Gloria Tridello4; Juana Schwartz4; Nina Knelange4; Arancha Bermudez Rodriguez5; Maria Suarez-Lledo6; Johan Maertens7; Maria Stamouli8; Francis Ayuk9; Candela Ceballos10; Maria Huguet11; Felipe Peña-Muñoz12; Pablo Granados13; Alienor Xhaard14; Jurgen Kuball15; Chiara Nozzoli16; Francesca Kinsella17; Alejandro Avendano18; Hakan Ozdogu19; Jose Rifon Roca20; Nicole Morrow21; Marta Stanzani22; Marina Popova23; Jerome Cornillon24; Tsila Zuckerman25; Massimo Martino26; Johannes Clausen27; Jan Styczynski28; Dina Averbuch29
|